TP53 and cancer: Regarding clinical trials studying statin’s significance on cancer inhibition, some phase 3 clinical trials were performed in hepatocellular carcinoma [94], gastric cancer [95], and small cell lung cancer (SCLC) [96]; however, none of these studies considered the p53 status in tumors.